NCT07785765

Brief Summary

The goal of this randomized clinical trial is to determine whether a supervised high-intensity interval training (HIIT) program can safely improve cardiorespiratory fitness and overall health in adults who have previously had spontaneous coronary artery dissection (SCAD), a non-atherosclerotic cause of heart attack that often affects younger women. Participants are women and men aged 18 years or older, with a confirmed SCAD at least 12 weeks before enrollment, who are medically stable, cleared for exercise testing, and able to attend supervised sessions. The main questions the study aims to answer are:

  • Does a 12-week supervised HIIT program lead to a greater improvement in cardiorespiratory fitness (measured as peak oxygen uptake (VO2peak, ml/kg/min)) compared with usual care, without increasing the occurrence of major adverse cardiovascular events (MACE)?
  • Is a 12-week HIIT program safe for people with prior SCAD, assessed by the occurrence of MACE? Researchers will compare two randomized groups (1:1):
  • Group A (HIIT): Participants take part in a supervised treadmill-based high-intensity interval training program twice per week for 12 weeks, with continuous heart rate monitoring and clear rules for stopping in case of symptoms.
  • Group B (usual care): Participants continue with the exercise advice they have already received after SCAD, without a structured supervised program and with a recommendation to avoid high-intensity exercise (above 85% of maximum heart rate). Participants in both groups will:
  • Undergo cardiopulmonary exercise testing (CPET) at baseline and after 12 weeks to measure VO2peak and blood pressure response during exercise.
  • Have blood tests (for example cholesterol and cardiac biomarkers), blood pressure, heart rate and weight measured.
  • Complete validated questionnaires on quality of life (World Health Organization Quality of Life-BREF (WHOQOL-BREF)), anxiety (Generalized Anxiety Disorder 7-item scale (GAD-7)), and depression (Patient Health Questionnaire-9 (PHQ-9)).
  • Have activity data recorded using the MIA activity-tracking app and heart rate data will be uploaded simultaneously from portable devices. Safety will be monitored continuously. Major adverse cardiovascular events (MACE), including death, recurrent heart attack (SCAD or non-SCAD), heart failure, stroke or transient ischemic attack, extracoronary arterial dissection, cardioversion or implantable cardioverter-defibrillator (ICD) therapy, will be recorded during the 12-week intervention and a 25-week follow-up period (total study duration per participant: 37 weeks).

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
17mo left

Started Jan 2027

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 14, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

August 25, 2026

Completed
4 months until next milestone

Study Start

First participant enrolled

January 1, 2027

Expected
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2028

5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2028

Last Updated

August 25, 2026

Status Verified

August 1, 2026

Enrollment Period

1 year

First QC Date

August 14, 2026

Last Update Submit

August 21, 2026

Conditions

Keywords

SCADExerciseHIITMACESpontaneous coronary artery dissectionHigh intensity interval training

Outcome Measures

Primary Outcomes (1)

  • Change from baseline to 12 weeks in peak oxygen uptake (VO2peak, ml/kg/min) measured by CPET

    From enrollment to the end of intervention (12 weeks)

Secondary Outcomes (9)

  • MACE (composite of recurrent SCAD, TIA/stroke, extra-coronary artery dissection,death and/or aborted cardiac arrest)

    From enrollment to end of follow-up period (12 weeks + 25 weeks)

  • Incidence of MACE (recurrent SCAD alone)

    From enrollment to end of follow-up period (12 weeks + 25 weeks)

  • Incidence of MACE (death or aborted cardiac arrest)

    From enrollment to end of follow-up period (12 weeks + 25 weeks)

  • Change in quality of life

    From enrollment to end of intervention (12 weeks)

  • Change in depression

    From enrollment to end of intervention (12 weeks)

  • +4 more secondary outcomes

Study Arms (2)

Group A - High intensity interval training (HIIT)

EXPERIMENTAL

Intervention

Other: High intensity interval training (HIIT)

Group B - Usual Care

NO INTERVENTION

Usual care with exercise restriction

Interventions

Participants take part in a supervised treadmill-based high-intensity interval training program twice per week for 12 weeks. Each session is 4 minutes x 4 at target heart rate between 85-95% of maximum HR.

Group A - High intensity interval training (HIIT)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Confirmed SCAD, at least 12 weeks since last event, age 18 years or older, medically stable and cleared for CPET and supervised exercise

You may not qualify if:

  • Disease with exercise restrictions, exercise related severe hypertension on CPET (\>220 mmHg in Systolic blood pressure or \>110mmHg in Diastolic blood pressure)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rikshospitalet, Department of Cardiology, ProCardio Center for Innovation

Oslo, 0372, Norway

Location

Related Publications (12)

  • Hilton SE, Thiessen JS, Rycroft AD, Miners NI, Bommarito JC, Matharu TS, Khangura PK, Stapleton RK, Rocha LC, Nardone M, Millar PJ. Influence of sex and aerobic fitness on blood pressure during maximal treadmill exercise in young healthy adults. J Appl Physiol (1985). 2025 Jun 1;138(6):1321-1326. doi: 10.1152/japplphysiol.00056.2025. Epub 2025 May 5.

    PMID: 40323584BACKGROUND
  • Schultz MG, Otahal P, Roberts-Thomson P, Stanton T, Hamilton-Craig C, Wahi S, La Gerche A, Hare JL, Selvanayagam J, Maiorana A, Venn AJ, Marwick TH, Sharman JE. Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study. Eur Heart J. 2026 Apr 7;47(14):1661-1671. doi: 10.1093/eurheartj/ehaf1082.

    PMID: 41528824BACKGROUND
  • De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, Cauldwell M, Cerbai E, Crotti L, de Groot NMS, Estensen ME, Goossens ES, Haring B, Kurpas D, McEniery CM, Peters SAE, Rakisheva A, Sambola A, Schlager O, Schoenhoff FS, Simoncini T, Steinbach F, Sudano I, Swan L, Valente AM; ESC Scientific Document Group. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025 Nov 14;46(43):4462-4568. doi: 10.1093/eurheartj/ehaf193. No abstract available.

    PMID: 40878294BACKGROUND
  • Heath A, Offringa M, Pechlivanoglou P, Rios JD, Klassen TP, Poonai N, Pullenayegum E; KidsCAN PERC Innovative Paediatric Clinical Trials Team. Determining a Bayesian predictive power stopping rule for futility in a non-inferiority trial with binary outcomes. Contemp Clin Trials Commun. 2020 Apr 8;18:100561. doi: 10.1016/j.conctc.2020.100561. eCollection 2020 Jun.

    PMID: 32300671BACKGROUND
  • Tucker WJ, Fegers-Wustrow I, Halle M, Haykowsky MJ, Chung EH, Kovacic JC. Exercise for Primary and Secondary Prevention of Cardiovascular Disease: JACC Focus Seminar 1/4. J Am Coll Cardiol. 2022 Sep 13;80(11):1091-1106. doi: 10.1016/j.jacc.2022.07.004.

    PMID: 36075680BACKGROUND
  • Kavanagh T, Mertens DJ, Hamm LF, Beyene J, Kennedy J, Corey P, Shephard RJ. Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. J Am Coll Cardiol. 2003 Dec 17;42(12):2139-43. doi: 10.1016/j.jacc.2003.07.028.

    PMID: 14680741BACKGROUND
  • Stensvold D, Viken H, Steinshamn SL, Dalen H, Stoylen A, Loennechen JP, Reitlo LS, Zisko N, Baekkerud FH, Tari AR, Sandbakk SB, Carlsen T, Ingebrigtsen JE, Lydersen S, Mattsson E, Anderssen SA, Fiatarone Singh MA, Coombes JS, Skogvoll E, Vatten LJ, Helbostad JL, Rognmo O, Wisloff U. Effect of exercise training for five years on all cause mortality in older adults-the Generation 100 study: randomised controlled trial. BMJ. 2020 Oct 7;371:m3485. doi: 10.1136/bmj.m3485.

    PMID: 33028588BACKGROUND
  • Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, Pieske-Kraigher E, Beckers P, Bobenko A, Hommel J, Van de Heyning CM, Esefeld K, von Korn P, Christle JW, Haykowsky MJ, Linke A, Wisloff U, Adams V, Pieske B, van Craenenbroeck EM, Halle M; OptimEx-Clin Study Group. Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2021 Feb 9;325(6):542-551. doi: 10.1001/jama.2020.26812.

    PMID: 33560320BACKGROUND
  • Battenberg AE, Carey P, Larson KF, Hayes SN, Smith JR, Baker SE, Bonikowske AR, Tweet MS. Spontaneous Coronary Artery Dissection in Highly Active Individuals: Insights From a Prospective Registry. JACC Adv. 2026 Feb;5(2):102485. doi: 10.1016/j.jacadv.2025.102485. Epub 2026 Jan 2.

    PMID: 41483544BACKGROUND
  • Chacin-Suarez AS, Bonikowske AR, Medina-Inojosa JR, Gulati R, Best PJ, Hayes SN, Tweet MS. Physical Activity and Exercise Patterns After Spontaneous Coronary Artery Dissection: Insights From a Large Multinational Registry. Front Cardiovasc Med. 2021 Jun 15;8:642739. doi: 10.3389/fcvm.2021.642739. eCollection 2021.

    PMID: 34212011BACKGROUND
  • Kim SK, Wing-Lun E, Chandrasekhar J, Puri A, Burgess S, Ford TJ, Kovacic J, Graham RM, Psaltis PJ, Zaman S. The Australian New Zealand Spontaneous Coronary Artery Dissection (ANZ-SCAD) Registry - A Multi-Centre Cohort Study: Protocol, Background and Significance. Heart Lung Circ. 2022 Dec;31(12):1612-1618. doi: 10.1016/j.hlc.2022.08.018. Epub 2022 Sep 28.

    PMID: 36180304BACKGROUND
  • Saw J, Starovoytov A, Aymong E, Inohara T, Alfadhel M, McAlister C, Samuel R, Grewal T, Parolis JA, Sheth T, So D, Minhas K, Brass N, Lavoie A, Bishop H, Lavi S, Pearce C, Renner S, Madan M, Welsh RC, McGrath BM, Vijayaraghavan R, Har B, Ibrahim R, Chaudhary P, Ganesh SK, Graham J, Matteau A, Martucci G, Ko DT, Humphries K, Mancini GJ. Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes. J Am Coll Cardiol. 2022 Oct 25;80(17):1585-1597. doi: 10.1016/j.jacc.2022.08.759.

    PMID: 36265953BACKGROUND

MeSH Terms

Conditions

Coronary Artery Dissection, SpontaneousMyocardial InfarctionMotor Activity

Interventions

High-Intensity Interval Training

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosisBehavior

Intervention Hierarchy (Ancestors)

Physical Conditioning, HumanExerciseMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Kristina Hermann Haugaa, Phd

    Rikshospitalet, Oslo Univeristy Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 14, 2026

First Posted

August 25, 2026

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

June 1, 2028

Last Updated

August 25, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

No plan to share individual participant data (IPD). Due to ethical and privacy considerations and limitations in the current consent and data governance framework, only aggregate (summary) results will be shared through publications and posting on ClinicalTrials.gov.

Locations